speb/financial-data huggingface dataset:
CYTO.V cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -74621.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -731153.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 4211020.00
CYTO.V income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 847507.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Gross PPE: 4629105.00
CYTO.V income_statement (quarterly, 2025-03-31) — Interest Expense: 24737.00
CYTO.V income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 24737.00
CYTO.V income_statement (quarterly, 2025-03-31) — Interest Income: 4518.00
CYTO.V income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 4518.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Invested Capital: 1771037.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -3139.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Leases: 1034588.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 1263368.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1263368.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -74621.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 500608.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -1160178.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Interest Income: -20219.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -74621.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -74621.00
CYTO.V income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -20219.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Net PPE: 2861758.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -3139.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 1771037.00
CYTO.V income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -880628.00
CYTO.V income_statement (quarterly, 2025-03-31) — Normalized Income: -1160178.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -728014.00
CYTO.V income_statement (quarterly, 2025-03-31) — Operating Income: -1139959.00
CYTO.V income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 53935221.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: -1.00
CYTO.V income_statement (quarterly, 2025-03-31) — Other Gand A: 344334.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 23357.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1.00
CYTO.V income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 14129.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Other Properties: 1282460.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Payables: 313664.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 523081.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 105290.00
CYTO.V income_statement (quarterly, 2025-03-31) — Pretax Income: -1160178.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -3139.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Receivables: 98974.00
CYTO.V income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 254813.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -74621.00
CYTO.V income_statement (quarterly, 2025-03-31) — Research And Development: 23510.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -27722670.00
CYTO.V income_statement (quarterly, 2025-03-31) — Salaries And Wages: 503173.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
CYTO.V income_statement (quarterly, 2025-03-31) — Selling General And Administration: 847507.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Share Issued: 53935221.00
CYTO.V income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 1771037.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 1771037.00
CYTO.V income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 75951.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Assets: 3781003.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 1771037.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Debt: 1486885.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 1771037.00
CYTO.V income_statement (quarterly, 2025-03-31) — Total Expenses: 1139959.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2009966.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 2861758.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1263369.00
CYTO.V income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Working Capital: 172648.00
CYTO.V income_statement (quarterly, 2025-06-30) — +Operating Expense: 1107890.00
CYTO.V income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 316444.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Accrued Interest Receivable: 3936.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -1947475.00
CYTO.V income_statement (quarterly, 2025-06-30) — Basic Average Shares: 55657443.00
CYTO.V income_statement (quarterly, 2025-06-30) — Basic EPS: -0.02
CYTO.V cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 714981.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 1811449.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -2.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 1434830.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Capital Stock: 26206950.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 1225042.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 1225042.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Cash Equivalents: 126589.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Cash Financial: 1098453.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 1416533.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -2.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -906470.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 13153.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 2624.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Change In Receivables: 8699.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 24476.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 23023.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Changes In Cash: 510061.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Common Stock: 26206950.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 2132486.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 1550000.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 219790.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Current Assets: 1421919.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 232139.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 232139.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 768373.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Depreciation: 180129.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 180129.00
CYTO.V income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 180129.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 180129.00
CYTO.V income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 180129.00
CYTO.V income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 180129.00
CYTO.V income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 55657443.00
CYTO.V income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.02
CYTO.V income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — EBIT: -1107103.00
CYTO.V income_statement (quarterly, 2025-06-30) — EBITDA: -926974.00
CYTO.V cash_flow (quarterly, 2025-06-30) — End Cash Position: 1225042.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 1416533.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -906472.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 4777910.00
CYTO.V income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 869623.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Gross PPE: 4629106.00
CYTO.V income_statement (quarterly, 2025-06-30) — Interest Expense: 22601.00
CYTO.V income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 22601.00
CYTO.V income_statement (quarterly, 2025-06-30) — Interest Income: 787.00
CYTO.V income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 787.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Invested Capital: 2132486.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -2.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 1550000.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Leases: 1034588.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 1202691.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 1202691.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -74620.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 500609.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 1550000.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -1129704.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -1129704.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Interest Income: -21814.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -74620.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -74620.00
CYTO.V income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -21814.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 2681631.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -2.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 2132486.00
CYTO.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -926974.00
CYTO.V income_statement (quarterly, 2025-06-30) — Normalized Income: -1129704.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -906470.00
CYTO.V income_statement (quarterly, 2025-06-30) — Operating Income: -1107890.00
CYTO.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 61685221.00
CYTO.V income_statement (quarterly, 2025-06-30) — Other Gand A: 400037.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 18629.00
CYTO.V income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 33619.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Other Properties: 1282460.00
CYTO.V income_statement (quarterly, 2025-06-30) — Other Taxes: -11081.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Payables: 316444.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 536234.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 102666.00
CYTO.V income_statement (quarterly, 2025-06-30) — Pretax Income: -1129704.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -2.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Receivables: 94211.00
CYTO.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 180129.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -74620.00
CYTO.V income_statement (quarterly, 2025-06-30) — Research And Development: 35600.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -28852374.00
CYTO.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 469586.00
CYTO.V cash_flow (quarterly, 2025-06-30) — Sale Of Business: 0.00
CYTO.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 869623.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 61685221.00
CYTO.V income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 2132486.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 2132486.00
CYTO.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 90275.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 4103550.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 2132486.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Debt: 1434830.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 2132486.00
CYTO.V income_statement (quarterly, 2025-06-30) — Total Expenses: 1107890.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 1971064.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 2681631.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 1202691.00
CYTO.V income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
CYTO.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 653546.00
CYTO.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 1012521.00
CYTO.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 423017.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 3980.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Accrued Interest Receivable: 2932.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -2034154.00
CYTO.V income_statement (quarterly, 2025-09-30) — Basic Average Shares: 61685221.00
CYTO.V income_statement (quarterly, 2025-09-30) — Basic EPS: -0.02
CYTO.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 1225042.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 1811449.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -9245.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 1381971.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 26206950.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 340981.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 340981.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 126589.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Cash Financial: 214392.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -74620.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -9245.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -800196.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 96030.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -15575.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: -24385.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 56070.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -3980.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: -884061.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 26206950.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 1166777.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 209247.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 576814.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 240895.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 240895.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 873159.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Depreciation: 86678.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 86678.00
CYTO.V income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 86678.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 86678.00
CYTO.V income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 86678.00
CYTO.V income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 86678.00
CYTO.V income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 61685221.00
CYTO.V income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.02
CYTO.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — EBIT: -1012521.00
CYTO.V income_statement (quarterly, 2025-09-30) — EBITDA: -925843.00
CYTO.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 340981.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -74620.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -809441.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 4847537.00
CYTO.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 809913.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Gross PPE: 4638352.00
CYTO.V income_statement (quarterly, 2025-09-30) — Interest Expense: 22815.00
CYTO.V income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 22815.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 1166777.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -9245.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Leases: 1034588.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 1141076.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 1141076.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -74620.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 500609.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -1035336.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -1035336.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Interest Income: -22815.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -74620.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -74620.00
CYTO.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -22815.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 2604198.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -9245.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 1166777.00
CYTO.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -925843.00
CYTO.V income_statement (quarterly, 2025-09-30) — Normalized Income: -1035336.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -800196.00
CYTO.V income_statement (quarterly, 2025-09-30) — Operating Income: -1012521.00
CYTO.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 61685221.00
CYTO.V income_statement (quarterly, 2025-09-30) — Other Gand A: 306840.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 22765.00
CYTO.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 41708.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Other Properties: 1291706.00
CYTO.V income_statement (quarterly, 2025-09-30) — Other Taxes: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Payables: 423017.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 632264.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 118241.00
CYTO.V income_statement (quarterly, 2025-09-30) — Pretax Income: -1035336.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -9245.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Receivables: 117592.00
CYTO.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 86678.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -74620.00
CYTO.V income_statement (quarterly, 2025-09-30) — Research And Development: 74222.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -29887710.00
CYTO.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 503073.00
CYTO.V cash_flow (quarterly, 2025-09-30) — Sale Of Business: 0.00
CYTO.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 809913.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 61685221.00
CYTO.V income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 1166777.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 1166777.00
CYTO.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 110680.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 3181012.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 1166777.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Debt: 1381971.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 1166777.00
CYTO.V income_statement (quarterly, 2025-09-30) — Total Expenses: 1012521.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2014235.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2604198.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1141076.00
CYTO.V income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
CYTO.V balance_sheet (quarterly, 2025-09-30) — Working Capital: -296345.00
CYTO.V income_statement (annual, 2025-12-31) — +Operating Expense: 4043004.00
CYTO.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 782634.00
CYTO.V income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Accounts Payable: 311331.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 311331.00
CYTO.V balance_sheet (annual, 2025-12-31) — Accounts Receivable: 153432.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 153432.00
CYTO.V balance_sheet (annual, 2025-12-31) — Accrued Interest Receivable: 0.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Accrued Interest Receivable: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -2191279.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -2191279.00
CYTO.V cash_flow (annual, 2025-12-31) — Beginning Cash Position: 1520755.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 340981.00
CYTO.V balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 1811449.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 1811449.00
CYTO.V cash_flow (annual, 2025-12-31) — Capital Expenditure: -12385.00
CYTO.V balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 1323123.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 1323123.00
CYTO.V balance_sheet (annual, 2025-12-31) — Capital Stock: 27230293.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 27230293.00
CYTO.V balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 500609.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 500609.00
CYTO.V balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 500609.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 500609.00
CYTO.V balance_sheet (annual, 2025-12-31) — Cash Equivalents: 0.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Cash Financial: 500609.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Cash Financial: 500609.00
CYTO.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 2419461.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1152169.00
CYTO.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -12385.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 1.00
CYTO.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -3427222.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -992542.00
CYTO.V cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -45904.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -209572.00
CYTO.V cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -10128.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 8696.00
CYTO.V cash_flow (annual, 2025-12-31) — Change In Receivables: -72485.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: -162181.00
CYTO.V cash_flow (annual, 2025-12-31) — Change In Working Capital: -128517.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -363057.00
CYTO.V cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -143340.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -149452.00
CYTO.V cash_flow (annual, 2025-12-31) — Changes In Cash: -1020146.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: 159628.00
CYTO.V balance_sheet (annual, 2025-12-31) — Common Stock: 27230293.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 27230293.00
CYTO.V balance_sheet (annual, 2025-12-31) — Common Stock Equity: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 1588252.00
CYTO.V cash_flow (annual, 2025-12-31) — Common Stock Issuance: 2750000.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 1200000.00
CYTO.V balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 111361.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 111361.00
CYTO.V balance_sheet (annual, 2025-12-31) — Current Assets: 886995.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 886995.00
CYTO.V balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 244613.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 244613.00
CYTO.V balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 244613.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 244613.00
CYTO.V balance_sheet (annual, 2025-12-31) — Current Liabilities: 667305.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 667305.00
CYTO.V cash_flow (annual, 2025-12-31) — Depreciation: 678745.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Depreciation: 157125.00
CYTO.V cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 678745.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 157125.00
CYTO.V income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 678745.00
CYTO.V income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 157125.00
CYTO.V cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 678745.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 157125.00
CYTO.V income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 678745.00
CYTO.V income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 157125.00
CYTO.V income_statement (annual, 2025-12-31) — Depreciation Income Statement: 678745.00
CYTO.V income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 157125.00
CYTO.V income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — EBIT: -4038485.00
CYTO.V income_statement (quarterly, 2025-12-31) — EBIT: -782416.00
CYTO.V income_statement (annual, 2025-12-31) — EBITDA: -3359740.00
CYTO.V income_statement (quarterly, 2025-12-31) — EBITDA: -625291.00
CYTO.V cash_flow (annual, 2025-12-31) — End Cash Position: 500609.00
CYTO.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 500609.00
CYTO.V cash_flow (annual, 2025-12-31) — Financing Cash Flow: 2419461.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 1152169.00
CYTO.V cash_flow (annual, 2025-12-31) — Free Cash Flow: -3439607.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -992541.00
CYTO.V balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 5051176.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 5051176.00
CYTO.V income_statement (annual, 2025-12-31) — General And Administrative Expense: 3207096.00
CYTO.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 680053.00
CYTO.V balance_sheet (annual, 2025-12-31) — Gross PPE: 4638351.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Gross PPE: 4638351.00
CYTO.V income_statement (annual, 2025-12-31) — Interest Expense: 92240.00
CYTO.V income_statement (quarterly, 2025-12-31) — Interest Expense: 23091.00
CYTO.V income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 92240.00
CYTO.V income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 23091.00
CYTO.V income_statement (annual, 2025-12-31) — Interest Income: 4519.00
CYTO.V income_statement (quarterly, 2025-12-31) — Interest Income: 218.00
CYTO.V income_statement (annual, 2025-12-31) — Interest Income Non Operating: 4519.00
CYTO.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 218.00
CYTO.V cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Invested Capital: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 1588252.00
CYTO.V cash_flow (annual, 2025-12-31) — Investing Cash Flow: -12385.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 1.00
CYTO.V cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 2750000.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 1200000.00
CYTO.V cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Leases: 1034588.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Leases: 1034588.00
CYTO.V balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 1078510.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 1078510.00
CYTO.V balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1078510.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1078510.00
CYTO.V cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -215026.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 8835.00
CYTO.V balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 500608.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 500608.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 2750000.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 1200000.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -805507.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -4130725.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -805507.00
CYTO.V income_statement (annual, 2025-12-31) — Net Interest Income: -87721.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Interest Income: -22873.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -215026.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 8835.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -215026.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 8835.00
CYTO.V income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -87721.00
CYTO.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -22873.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -115513.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -56666.00
CYTO.V balance_sheet (annual, 2025-12-31) — Net PPE: 2447072.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 2447072.00
CYTO.V cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -12385.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 1.00
CYTO.V cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 1588252.00
CYTO.V income_statement (annual, 2025-12-31) — Normalized EBITDA: -3359740.00
CYTO.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -625291.00
CYTO.V income_statement (annual, 2025-12-31) — Normalized Income: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Normalized Income: -805507.00
CYTO.V cash_flow (annual, 2025-12-31) — Operating Cash Flow: -3427222.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -992542.00
CYTO.V income_statement (annual, 2025-12-31) — Operating Income: -4043004.00
CYTO.V income_statement (quarterly, 2025-12-31) — Operating Income: -782634.00
CYTO.V income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 67685221.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 67685221.00
CYTO.V income_statement (annual, 2025-12-31) — Other Gand A: 1348039.00
CYTO.V income_statement (quarterly, 2025-12-31) — Other Gand A: 296828.00
CYTO.V income_statement (annual, 2025-12-31) — Other Operating Expenses: 124354.00
CYTO.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 34898.00
CYTO.V balance_sheet (annual, 2025-12-31) — Other Properties: 1291706.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Other Properties: 1291706.00
CYTO.V income_statement (annual, 2025-12-31) — Other Taxes: -160777.00
CYTO.V income_statement (quarterly, 2025-12-31) — Other Taxes: -149696.00
CYTO.V balance_sheet (annual, 2025-12-31) — Payables: 311331.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Payables: 311331.00
CYTO.V balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 422692.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 422692.00
CYTO.V balance_sheet (annual, 2025-12-31) — Prepaid Assets: 109545.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 109545.00
CYTO.V income_statement (annual, 2025-12-31) — Pretax Income: -4130725.00
CYTO.V income_statement (quarterly, 2025-12-31) — Pretax Income: -805507.00
CYTO.V cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Properties: 0.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
CYTO.V cash_flow (annual, 2025-12-31) — Purchase Of PPE: -12385.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: 1.00
CYTO.V balance_sheet (annual, 2025-12-31) — Receivables: 276841.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Receivables: 276841.00
CYTO.V income_statement (annual, 2025-12-31) — Reconciled Depreciation: 678745.00
CYTO.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 157125.00
CYTO.V cash_flow (annual, 2025-12-31) — Repayment Of Debt: -215026.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: 8835.00
CYTO.V income_statement (annual, 2025-12-31) — Research And Development: 193586.00
CYTO.V income_statement (quarterly, 2025-12-31) — Research And Development: 60254.00
CYTO.V balance_sheet (annual, 2025-12-31) — Retained Earnings: -30693217.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -30693217.00
CYTO.V income_statement (annual, 2025-12-31) — Salaries And Wages: 1859057.00
CYTO.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 383225.00
CYTO.V cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Sale Of Business: 0.00
CYTO.V income_statement (annual, 2025-12-31) — Selling General And Administration: 3207096.00
CYTO.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 680053.00
CYTO.V balance_sheet (annual, 2025-12-31) — Share Issued: 67685221.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 67685221.00
CYTO.V cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 0.00
CYTO.V income_statement (annual, 2025-12-31) — Special Income Charges: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
CYTO.V cash_flow (annual, 2025-12-31) — Stock Based Compensation: 153275.00
CYTO.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 83648.00
CYTO.V balance_sheet (annual, 2025-12-31) — Stockholders Equity: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 1588252.00
CYTO.V balance_sheet (annual, 2025-12-31) — Tangible Book Value: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 1588252.00
CYTO.V income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Taxes Receivable: 123409.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 123409.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Assets: 3334067.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 3334067.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Capitalization: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1588252.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Debt: 1323123.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Debt: 1323123.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 1588252.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 1588252.00
CYTO.V income_statement (annual, 2025-12-31) — Total Expenses: 4043004.00
CYTO.V income_statement (quarterly, 2025-12-31) — Total Expenses: 782634.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 1745815.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 1745815.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 2447072.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 2447072.00
CYTO.V balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1078510.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1078510.00
CYTO.V income_statement (annual, 2025-12-31) — Total Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
CYTO.V income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
CYTO.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
CYTO.V balance_sheet (annual, 2025-12-31) — Working Capital: 219690.00
CYTO.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 219690.00
CYVIZ.OL balance_sheet (annual, 2021-12-31) — Allowance For Doubtful Accounts Receivable: -4677000.00
CYVIZ.OL income_statement (annual, 2021-12-31) — Basic Average Shares: 12885597.00
CYVIZ.OL income_statement (annual, 2021-12-31) — Basic EPS: -2.31
CYVIZ.OL balance_sheet (annual, 2021-12-31) — Cash And Cash Equivalents: 46494000.00
CYVIZ.OL balance_sheet (annual, 2021-12-31) — Cash Cash Equivalents And Short Term Investments: 46494000.00
CYVIZ.OL cash_flow (annual, 2021-12-31) — Change In Other Current Assets: 1278000.00
CYVIZ.OL income_statement (annual, 2021-12-31) — Diluted Average Shares: 12885597.00
CYVIZ.OL income_statement (annual, 2021-12-31) — Diluted EPS: -2.31
CYVIZ.OL balance_sheet (annual, 2021-12-31) — Gross Accounts Receivable: 86649000.00
CYVIZ.OL cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
CYVIZ.OL cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
CYVIZ.OL balance_sheet (annual, 2021-12-31) — Other Current Assets: 1000.00
CYVIZ.OL income_statement (annual, 2022-12-31) — +Operating Expense: 231195000.00
CYVIZ.OL income_statement (annual, 2022-12-31) — +Total Revenue: 485967000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Accounts Payable: 74136000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Accounts Receivable: 136409000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -71381000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 84474000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -2339000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 15677000.00
CYVIZ.OL income_statement (annual, 2022-12-31) — Basic Average Shares: 12885597.00
CYVIZ.OL income_statement (annual, 2022-12-31) — Basic EPS: -1.50
CYVIZ.OL cash_flow (annual, 2022-12-31) — Beginning Cash Position: 48510000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Capital Expenditure: -33571000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Capital Stock: 14174000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 11366000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 11366000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 29276000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Change In Inventory: -4412000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Change In Payable: 27413000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Change In Receivables: -54437000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Change In Working Capital: -2160000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Changes In Cash: -34653000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Common Stock: 14174000.00
CYVIZ.OL balance_sheet (annual, 2022-12-31) — Common Stock Equity: 98648000.00
CYVIZ.OL cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
CYVIZ.OL income_statement (annual, 2022-12-31) — Cost Of Revenue: 265772000.00